Erastapex Co 5mg / 40mg 30 tablets

Tradename

Erastapex Co

Composition

Each tablet contains:

Olmesartanmedoxomil 40 mg

Amlodipine 5 mg

Auxiliary components:

pregelatinized starch, microcrystalline siliconized cellulose, croscarmellose sodium, magnesium stearate.

Properties

Combined antihypertensive drug, which includes an angiotensin Il receptor antagonist olmesartanmedoxomil and a slow calcium channel blocker — amlodipine. The combination of the two active ingredients has a synergistic antihypertensive effect, as a result of which blood pressure decreases to a greater extent than when each of them is taken separately.

Indications

Essential hypertension (with the ineffectiveness of olmesartan monotherapy with medoxomil or amlodipine).

Method of administration and dosage:

The drug is taken orally, 1 time / day, at the same time, regardless of the time of meals, without chewing, drinking a sufficient amount of liquid (for example, a glass of water).

Contraindications

Severe liver failure (more than 9 points on the Child-Pugh scale); obstruction of the biliary tract and cholestasis; renal failure of severe severity (CC less than 20 ml / min, there is no clinical experience); condition after kidney transplantation (there is no clinical experience); conditions accompanied by severe impairment of blood outflow from the left ventricle (for example, severe aortic stenosis); severe arterial hypotension (SBP less than 90 mm Hg); shock (including cardiogenic); hemodynamically unstable heart failure after myocardial infarction; simultaneous use with aliskiren and

aliskiren-containing drugs in patients with diabetes mellitus and / or impaired renal function (GFR less than 60 ml / min / 1.732m of body surface area); pregnancy; breastfeeding period; age up to 18 years (efficacy and safety have not been established); hypersensitivity to olmesartanmedoxomil, amlodipine and other dihydropyridine derivatives or to other components of the drug.

With care: stenosis of the aortic and mitral valves; hypertrophic obstructive cardiomyopathy; simultaneous use with lithium preparations; hyperkalemia, hyponatremia; hypovolemia (including due to diarrhea, vomiting, or the simultaneous use of diuretics), as well as in patients on a diet with limited salt intake; renal failure of mild to moderate severity (CC 20-60 ml / min); primary aldosteronism; renovascular hypertension (bilateral stenosis of the renal arteries or stenosis of an artery of a single kidney); other conditions accompanied by activation of the RAAS; chronic heart failure (Ill-IV FC according to NYHA classification); chronic forms of ischemic heart disease; acute forms of ischemic heart disease (acute myocardial infarction, including within one month after it; ectoris): SSSU: arterial

Side effects

From the immune system: rarely — allergic reactions, hypersensitivity reactions, urticaria.

From the side of the nervous system: often dizziness, headache; infrequently hypesthesia, paresthesia, postural dizziness, drowsiness; rarely syncope.

Mental disorders: infrequently — decreased libido.